Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R

OBJECTIVE: Combined overall survival (OS) analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor (EGFR) exon 19 deletions (Del19) would benefit from first-line second generation EGFR tyrosine kinase inhibitors (TKIs) afatinib but not for those with L85...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Wei, Lei, Yuanyuan, Liu, Siyang, Yang, Jinji, Tu, Haiyan, Yan, Honghong, Wu, Yilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949279/
https://www.ncbi.nlm.nih.gov/pubmed/27478319
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.03.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949279/
https://www.ncbi.nlm.nih.gov/pubmed/27478319
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.03.08

Ejemplares similares